A Phase II Study of Erlotinib and Radiation Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck.

Trial Profile

A Phase II Study of Erlotinib and Radiation Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2012

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Oct 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 11 May 2012 Actual patient number is 2 as reported by ClinicalTrials.gov.
    • 11 May 2012 Planned end date changed from 1 May 2012 to 1 May 2017 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top